See the latest news and media coverage for BMS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global biopharmaceutical company
bms.comLast updated
In short: BMS reported strong Q2 2026 earnings, secured FDA approval for the schizophrenia drug Cobenfy, and expanded its manufacturing footprint.
The registrational Phase 2 QUINTESSENTIAL study met primary and secondary endpoints for arlocabtagene autoleucel in heavily pretreated multiple myeloma patients. The safety profile aligns with expectations. Results will be presented at an upcoming medical conference.
Led by RayzeBio, the initiative creates jobs, positions Indiana as a life sciences hub, and accelerates delivery of next-generation cancer therapies.
The CELMoD therapy treats relapsed or refractory multiple myeloma patients who have received prior proteasome inhibitor and immunomodulatory therapy regimens.
The investment will create nearly 500 skilled jobs and supports a $40 billion five-year US investment across R&D, technology, and manufacturing.
FDA has granted accelerated approval to Zenbexus plus daratumumab and Hyaluronidase-fihj and...
The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel...
When the transaction is completed, BMS shareholders are projected to own about 69% of the company, while Celgene shareholders are expected to own approximately 31...
Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead...
Track BMS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to BMS and other trending companies.